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Abstract 
Significant insight into the mechanisms that contribute to dopaminergic neurodegeneration in 
Parkinson disease has been gained from the analysis of genes linked to rare heritable forms of 
parkinsonism such as PINK1 and parkin, loss-of-function mutations of which cause 
autosomal recessive parkinsonism. PINK1 encodes a mitochondrially targeted Ser/Thr kinase 
and parkin encodes a ubiquitin-protein ligase.  Functional studies of PINK1 and Parkin in 
animal and cellular model systems have shown that both proteins play important roles in 
maintaining mitochondrial integrity. Genetic studies of PINK1 and Parkin orthologs in flies 
have shown that PINK1 acts upstream from Parkin in a common pathway that appears to 
regulate mitochondrial morphology. Mitochondrial morphology is regulated by mitochondrial 
fission and fusion-promoting proteins, and is important in a variety of contexts, including 
mitochondrial trafficking and mitochondrial quality control. In particular, mitochondrial 
fission appears to promote the segregation of terminally dysfunctional mitochondria for 
degradation in the lysosome through a process termed mitophagy. Recent work has shown 
that Parkin promotes the degradation of dysfunctional mitochondria in vertebrate cell culture. 
Here we postulate a model whereby the PINK1/Parkin pathway regulates mitochondrial 
dynamics in an effort to promote the turnover of damaged mitochondria.  
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The mechanisms underlying dopamine neuron degeneration in Parkinson’s disease (PD) are 
incompletely understood, although increasing evidence suggests that mitochondrial 
dysfunction is a major contributor: several different mitochondrial complex I inhibitors elicit 
parkinsonian-like syndromes in humans and animal models (Betarbet et al. 2002; Corti et al. 
2005); a high proportion of sporadic PD patients exhibit systemic mitochondrial defects 
(Schapira 2007); mitochondrial DNA deletions are present at high abundance in dopamine 
neurons from aged individuals, and are even more prevalent in PD individuals (Bender et al. 
2006; Kraytsberg et al. 2006); and functional studies of the genes causative for simple 
Mendelian forms of PD suggest that many have mitochondrial roles (Abou-Sleiman et al. 
2006).  Although, there are reports in the literature that potentially implicate all of the PD-
related genes in mitochondrial dysfunction, the evidence is perhaps strongest for the PINK1 
and Parkin, genes, which are the focus of this review. 
 
Loss-of-function mutations in PINK1 and parkin are the primary cause of early-onset 
autosomal recessive forms of PD (Gasser 2009). The PINK1 gene encodes a mitochondrially 
targeted Ser/Thr kinase, whereas parkin encodes an E3 ubiquitin-protein ligase. The 
subcellular distribution of PINK1 and Parkin is a matter of some dispute, although there is 
broad agreement that at least some fraction of PINK1 protein localizes to mitochondria with 
its kinase domain facing the inter-membrane space or the cytoplasm (Gandhi et al. 2006; 
Zhou et al. 2008), and that Parkin is predominantly a cytosolic protein. To understand the 
mechanism by which PINK1 and Parkin influence dopamine neuron integrity, much of the 
early work on these factors involved a search for their substrates. To identify these substrates 
investigators sought proteins that bind to PINK1 and Parkin, and also tested candidate 
proteins implicated in PD pathogenesis. While these approaches have led to the identification 
of a number of putative PINK1 and Parkin substrates, in vivo evidence supporting a 
pathogenic role for many of these substrates is lacking, and only a subset of these putative 
substrates have been independently validated in multiple model systems. 
 
Using a complementary approach to understand the biological roles of PINK1 and Parkin, 
animal models of PD were created by inactivating the PINK1 and parkin genes in worms, 
flies, fish and mice and studying the consequences of these knockouts.  In this review we 
focus on the work performed in mice and flies, which have had the biggest impacts on our 
current thinking about the biological roles of PINK1 and Parkin. Although mice bearing 
knockouts of the PINK1 and parkin genes have mild phenotypes and do not recapitulate the 
dopamine neuron loss observed in humans (Kitada et al. 2009), these mice do have 
nigrostriatal physiological defects suggesting a role for PINK1 and Parkin in dopamine 
neurotransmission (Goldberg et al. 2003; Kitada et al. 2007; Kitada et al. 2009). The PINK1 
and parkin knockout mice have also proven useful in experiments to test the validity of 
putative substrates of PINK1 and Parkin, and to explore models of pathogenesis (e.g., see 
(Goldberg et al. 2003) and (von Coelln et al. 2006)). By contrast, flies bearing knockouts of 
the PINK1 and parkin genes have dramatic phenotypes, including progressive degeneration 
of a subset of dopamine neurons in the brain, degeneration of flight muscle tissue, and 
defective sperm cell development (Greene et al. 2003; Clark et al. 2006; Park et al. 2006). 
Interestingly, enlarged and swollen mitochondria are a prominent and early feature of all of 
the tissues affected by loss of PINK1 and Parkin, suggesting that these factors act to 
influence mitochondrial integrity. Although this finding was not particularly surprising for 
PINK1 given that it bears a targeting sequence directing it to mitochondria, these studies 
provided the first evidence that Parkin promotes mitochondrial integrity (Greene et al. 2003). 
 
Owing to the striking similarity of the Drosophila PINK1 and parkin mutant phenotypes 
studies were performed to test whether PINK1 and Parkin act in a common pathway. These 
studies yielded three lines of evidence in support of this conclusion: First, PINK1:parkin 
double mutants have similar phenotypes as the respective single mutants (Clark et al. 2006; 
Park et al. 2006). Second, overexpression of parkin was able to compensate for loss of 
PINK1 but not vice versa, suggesting that Parkin acts downstream from PINK1 (Clark et al. 
2006; Park et al. 2006; Yang et al. 2006).; Third, null mutations of parkin partially suppress a 
PINK1 overexpression phenotype (Poole et al. 2008; Whitworth et al. 2008), providing 
additional support for the model that PINK1 acts upstream from Parkin in a common 
pathway that regulates mitochondrial integrity. These important findings have since been 
validated in mammalian cellular models (Exner et al. 2007; Dagda et al. 2009). A major 
question remaining from these studies was precisely how PINK1 and Parkin influence 
mitochondrial integrity.    
 
An important clue into the possible mechanism by which PINK1 and Parkin influence 
mitochondrial integrity was provided by the finding that mutations in Drosophila PINK1 and 
parkin influence the morphology of mitochondria. Although mitochondria are often depicted 
as static kidney bean shaped organelles, mitochondria are highly motile and fuse with one 
another to form interconnected tubular networks. These dynamic networks undergo continual 
cycles of fission and fusion controlled by evolutionarily conserved fission- and fusion-
promoting factors(Detmer and Chan 2007). Among the known mitochondrial fission and 
fusion promoting factors are the large dynamin-related GTPases Dynamin-related protein 1 
(Drp1), Optic Atrophy 1 (Opa1) and Mitofusin (Mfn) (Detmer and Chan 2007). Drp1 is a 
cytosolic factor that assembles with mitochondria to promote mitochondrial fission, whereas 
Opa1 and Mfn reside in the inner and outer mitochondrial membranes, respectively, where 
they act to promote mitochondrial fusion (Detmer and Chan 2007). Given that mutations in 
PINK1 and parkin influence mitochondrial morphology, we and several other laboratories 
tested the hypothesis that PINK1 and Parkin regulate mitochondrial morphology. These 
studies revealed that removing a single copy of the fission-promoting factor Drp1 in PINK1 
or parkin mutants dramatically reduces their viability. In contrast, PINK1 and parkin mutant 
phenotypes are suppressed by overexpressing Drp1 to enhance mitochondrial fission, or by 
introducing loss-of-function mutations in genes encoding the fusion-promoting factors Opa1 
and Mfn (Deng et al. 2008; Poole et al. 2008; Yang et al. 2008; Park et al. 2009). Together, 
these findings suggest that the PINK1/Parkin pathway promotes mitochondrial fission and/or 
inhibits mitochondrial fusion. However, two observations indicate that PINK1 and Parkin are 
not obligatory components of the mitochondrial morphogenesis machinery: first, Opa1, Drp1 
and Mfn are conserved from yeast to mammals, but PINK1 and Parkin are only found in 
metazoans; second, null mutations in PINK1 and parkin result in less severe phenotypes than 
null mutations in Opa1, Drp1 and Mfn, Thus, PINK1 and Parkin may regulate the 
mitochondrial morphogenesis machinery in biological contexts that are particularly relevant 
to metazoans. 
 
While the biological roles of mitochondrial fission have not yet been extensively studied in 
metazoans, previous work suggests several possible mechanisms by which derangements in 
mitochondrial fission could impact tissue viability. One possible mechanism derives from 
genetic studies of the fission-promoting factor Drp1 in Drosophila. Loss-of-function 
mutations in Drosophila Drp1 result in a failure to efficiently traffic mitochondria to 
presynaptic terminals in neurons, which in turn impairs calcium buffering and synaptic 
transmission (Verstreken et al. 2005). While these findings are consistent with some of the 
phenotypes documented in PINK1 and Parkin-deficient flies and mice, the distribution of 
mitochondria in motor neurons appears to be unaffected in PINK1-deficient flies (Morais et 
al. 2009), and a mitochondrial trafficking defect does not readily account for the flight 
muscle and male germline defects of PINK1 and Parkin deficient flies, and the selective 
vulnerability of dopaminergic neurons to loss of PINK1 and Parkin activity.  
 
Another possible model by which defective mitochondrial fission could impact tissue 
viability derives from a recent study involving live-cell imaging of mitochondrial dynamics 
in cultured vertebrate cells (Twig et al. 2008). This study showed that while many products 
of mitochondrial fission rapidly fuse again with the mitochondrial network, a proportion of 
the fission products exhibit a decreased membrane potential and a decreased probability of 
fusion. These defective fission products are frequently targeted to the lysosome for 
degradation through a process termed mitophagy (Twig et al. 2008). Thus, these findings 
raise the possibility that derangements in PINK1 and Parkin could impair the selective 
turnover of damaged and dysfunctional mitochondria. Recent work provides support for this 
hypothesis by showing that Parkin is selectively recruited from the cytoplasm to damaged 
mitochondria upon treatment of cultured cells with mitochondrial damaging agents, and that 
Parkin is required for the turnover of these damaged mitochondria (Narendra et al. 2008). 
While these findings require independent replication, and further work will be required to test 
whether PINK1 is required for the mitophagy-promoting activity of Parkin, the findings of 
Narendra, et al, are attractive for several reasons: first, they offer an explanation for the 
variety of mitochondrial defects that have been documented in PINK1 and Parkin-deficient 
cell lines, including decreased membrane potential, deficits in the electron transport chain 
complexes, reduced ATP synthesis, decreased mitochondrial DNA synthesis and aberrant 
mitochondrial calcium efflux (Gandhi et al. 2009; Gegg et al. 2009; Morais et al. 2009) by 
suggesting that these pleiotropic phenotypes derive from the accumulation of damaged 
mitochondria in the absence of a functional mitochondrial quality control system; second, 
these findings would explain the protective effects of PINK1 and Parkin overexpression  
from exposure to mitochondrial toxins (Rosen et al. 2006; Paterna et al. 2007; Haque et al. 
2008); and third, the abundant mitochondrial DNA mutational load of dopaminergic neurons 
(Bender et al. 2006; Kraytsberg et al. 2006) would neatly account for the selective 
vulnerability of this population of cells to the loss of a mitochondrial quality control system. 
 
A model that combines work from flies showing that PINK1 acts upstream of Parkin to 
promote mitochondrial fission and the work of Narendra et al, demonstrating a role for Parkin 
in mitophagy is shown in Figure 1. While this model is consistent with much of the literature 
on PINK1 and Parkin, it is important to point out that the molecular mechanisms by which 
PINK1 and Parkin regulate mitochondrial fission and mitophagy, and indeed the very role of 
PINK1 in mitophagy are currently unknown, so this model should be considered tentative. 
Moreover, several recent findings have challenged features of this model. In particular, some 
of the studies of PINK1 in vertebrate systems have found that reduced PINK1 activity results 
in mitochondrial fragmentation (Exner et al. 2007; Dagda et al. 2009; Lutz et al. 2009; 
Sandebring et al. 2009), suggesting that PINK1 may promote mitochondrial fusion - exactly 
the opposite of the conclusion drawn from studies in flies. Another recent study has found 
that RNAi-mediated knockdown of PINK1 results in increased mitochondrial autophagy 
(Dagda et al. 2009), a finding that conflicts with a prediction of our model in Figure 1. 
Indeed, even the work of Narendra, et al, upon which our model is heavily based, suggests 
that Parkin is required for mitophagy at a step downstream of mitochondrial fission, thus 
raising the possibility that the beneficial effects of promoting increased fragmentation in 
Drosophila PINK1 and parkin mutants stems from the mitophagy promoting effects of 
mitochondrial fission. 
 
While additional work will likely invoke revisions to the model presented in Figure 1, it is 
important to point out that this model is primarily intended as a guide to future investigation. 
However, it is also important to add that some of the apparently discordant findings have 
multiple interpretations, not all of which conflict with our proposed model. For example, the 
finding of Narendra et al, suggesting that Parkin plays a post-fission role in mitochondrial 
turnover could be explained by a molecular event that marks the mitochondria for destruction 
while simultaneously inhibiting mitochondrial fusion. For example, Parkin-mediated 
ubiquitination of Mfn could inactivate the fusion-promoting function of Mfn, thus  triggering 
mitochondrial fragmentation, and the ubiquitinated Mfn could simultaneously serve as a tag 
marking the mitochondria for destruction by mitophagy (Figure 1). In potential support of 
this model, recent work has shown that ubiquitin can serve as a tag for the destruction of 
peroxisomes (Kim et al. 2008). Additionally, the finding that mitochondrial fragmentation 
and enhanced mitophagy result from reduced PINK1 activity in vertebrate systems may 
simply reflect a compensatory global induction of these processes in PINK1-deficient 
vertebrate cells. In potential support of this model is the finding that while the mitochondrial 
fragmentation seen in PINK1-deficient vertebrate cells can be suppressed by inactivating 
Drp1, this manipulation enhances the cell death associated with PINK1-deficiency (Dagda et 
al. 2009), a finding that is entirely consistent with work in flies. Future work should resolve 
these conflicts and clarify the mechanism by which PINK1 and Parkin influence 
mitochondrial integrity. 
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Figure 1.  
Proposed models by which the PINK1/Parkin pathway influences mitochondrial 
integrity. Both models postulate that the PINK1 kinase directly or indirectly senses 
mitochondrial damage resulting from mitochondrial DNA deletions, toxins, oxidative stress, 
or other sources and communicates this information to its substrates. Models 1 and 2 differ 
from one another in terms of the subcellular distribution of PINK1, which has been reported 
to localize to the intermembrane space (Pridgeon et al. 2007), to the cytoplasm as a soluble 
protein(Beilina et al. 2005; Lin and Kang 2008; Weihofen et al. 2008), and anchored to 
mitochondria with its kinase domain facing the cytoplasm (Zhou et al. 2008), and in terms of 
the possible substrates of PINK1. In model 1, a proteolytically processed, soluble form of 
PINK1 is exported from the inter membrane space of damaged mitochondria to 
phosphorylate (P) its possible substrates in the cytoplasm. In model 2, PINK1 anchored to 
mitochondria with its kinase domain facing the cytoplasm phosphorylates its cytoplasmic 
substrates upon mitochondrial damage. In Model 1, PINK1 phosphorylates cytoplasmically 
localized Parkin, thereby inducing Parkin to translocate to mitochondria and ubiquitinate 
(Ub) its mitochondrial target proteins. In Model 2, PINK1 phosphorylates proteins residing 
on the outer mitochondrial membrane, which in turn elicits the recruitment of Parkin to 
ubiquitinate these phosphorylated mitochondrial proteins. It should be emphasized that the 
PINK1 substrates in the two models are potentially interchangeable (i.e., soluble PINK1 in 
Model 1 could proceed to phosphorylate mitochondrial proteins, and membrane localized 
PINK1 in model 2 could phosphorylate Parkin). Excellent candidate targets of PINK1/Parkin 
include the fission-promoting factor Fis1 and the fusion-promoting factor Mfn, both of which 
reside on the outer mitochondrial membrane. Ubiquitination of Fis1 could serve to activate its 
fission-promoting function, which could involve the recruitment of Drp1 from the cytoplasm 
to initiate the fission event. Alternatively, ubiquitination of mitofusin could lead to its 
inactivation to promote the segregation of terminally damaged mitochondria that are unable 
to re-fuse with the mitochondrial network, while simultaneously labeling them for 
degradation by mitophagy. 
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